AstraZeneca (AZN) to Release Earnings on Thursday

AstraZeneca (NASDAQ:AZN) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $1.10 per share and revenue of $14.19 billion for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company earned $0.87 EPS. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, analysts expect AstraZeneca to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $70.25 on Thursday. The company has a market capitalization of $217.85 billion, a PE ratio of 33.61, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.68. The firm has a fifty day simple moving average of $66.69 and a 200 day simple moving average of $74.02.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.